Archive
544 articles, sorted by publication time.
Lilly and Astellas are said to be evaluating Sangamo’s assets, making the plight of a long-established gene-editing company more than an isolated financial event and reflecting the repricing of high-cost cell and gene therapies during a capital winter.
In a cancer type lacking hormone and HER2 targets, the significance of sacituzumab govitecan is not that it promises a cure, but that it offers patients whose disease continues to worsen after multiple lines of therapy a new option with clinical responses as well as clear toxicity costs.
Oncodaily focuses on Enrique Soto Perez de Celis’s warning about the evidence gap for older adults with cancer: as the people receiving treatment grow older, clinical trials often still lack sufficient representation, leaving precision medicine without one of its most everyday and most difficult pieces of the puzzle.
AIPOCH has launched MedSkillAudit, which breaks down the “skills” of medical AI agents and audits them item by item; preliminary research shows that most tested skills have not yet reached the threshold for limited release, and also underscores that medical AI governance cannot look only at model scores.
This is not a clinical data breakthrough, but it does reveal how capital markets re-label the maturity of a biotech company: when an R&D-driven drugmaker is placed in a value benchmark, investors are looking not only at the story, but also at revenue, valuation, and risk profile.
After re-examination, the CHMP shifted to a positive opinion, bringing trofinetide closer to EU approval; the rare disease drug offers the possibility of symptom improvement while putting the scale of clinical evidence, side-effect burden, and regulatory trade-offs in the spotlight.
AI’s entry into drug development is no longer just a showcase of model capabilities. This South Korean competition focuses on verifiable R&D tasks: data, prediction, and the gap with experimentation will determine technological value more than slogans.
The U.S. regulator is bringing artificial intelligence into clinical trial monitoring. The focus is not on letting machines make judgments about drugs, but on testing whether safety and efficacy signals can be seen earlier.
At a time when antibiotics and complex manufacturing processes are once again becoming issues of medical resilience, a senior scientific appointment reflects how an established drugmaker is strengthening the links between R&D, manufacturing and product strategy.
Whether a company can make it through Phase 3 trials often depends not only on the biological hypothesis behind a drug candidate, but also on whether it has enough funding to support recruitment, follow-up, and regulatory communication. Helus Pharma’s latest development falls squarely at this most practical threshold of clinical development.
Not long after acquiring new clinical assets, Nuvectis is seeking to replenish capital, underscoring how, when small biotech companies advance cancer and immunotherapy programs, the scientific narrative quickly returns to cash, trial cadence, and the maturity of evidence.
A USC team has turned originally short-lived immune progenitor cells into a platform that can be expanded and engineered long-term in the laboratory. It remains far from the clinic, but points to a vision of cancer immunotherapy that could be more standardized and prepared in advance.